tbuckley/cabot-search huggingface dataset:
78P Association between obesity, sex, and overall survival in patients with metastatic cancers treated with first- or second-line immune checkpoint inhibitors
Authors: M. Li, S. Zhao, J. Guo, M. Husain, J. Schafer, K. Chakravarthy, G. Lopez, D. Spakowicz, L. Wei, E. Bertino, A. Alahmadi, R. Memmott, J. Kaufman, K. He, C. Presley, P. Shields, D.P. Carbone, G.A. Otterson, D.H. Owen
Journal: Annals of Oncology (2022)
100P Co-mutational landscape of key fibroblast growth factor receptor (FGFR) alterations in intra-hepatic cholangiocarcinoma (iCCA), bladder cancer (BC) and glioma
Authors: A. Necchi, K. Murugesan, T. Burn, O. Gjoerup, R. Greenstein, J.A. López, M. Montesion, H. Nimeiri, A.R. Parikh, S. Roychowdhury, S. Schwemmers, I.M. Silverman, A. Vogel
Journal: Annals of Oncology (2022)
836P Outcome of PD-1 inhibitor therapy of advanced melanoma patients according to demographic factors in a real-world setting across Europe
Authors: M. Weichenthal, I-M. Svane, L. Kandolf Sekulovic, J. Mangana, I. Lugowska, P. Mohr, E. Espinosa, H.J. Gogas, M. Bender, E. Ellebæk, I. Gavrilova, D. Herceg, E. Muñoz Couselo, H. Schmidt, D. Stulhofer Buzina, P. Rutkowski, P.A. Ascierto, R. Dummer, D. Schadendorf, L. Bastholt
Journal: Annals of Oncology (2022)
810P PRESERV MEL: Real-world outcomes and health-related quality of life (HRQoL) in patients receiving adjuvant nivolumab for melanoma in Belgium and Luxembourg
Authors: A. Rogiers, L. Willemot, L. McDonald, H. Van Campenhout, K. Vouk, G. Berchem, C. Jacobs, A. Rorive, B. Neyns
Journal: Annals of Oncology (2022)
730MO First-in-human phase I study of INCAGN02390, a TIM-3 monoclonal antibody antagonist in patients with advanced malignancies
Authors: M.E. Gutierrez, S-C. Tang, J.D. Powderly, A.S. Balmanoukian, J. Janik, P. Hoyle, W. Wei, X. Gong, O. Hamid
Journal: Annals of Oncology (2022)
201TiP Density lowering effect of ovarian function suppression in premenopausal breast cancer patients who had no density change with one year of tamoxifen treatment (DELFINO study)
Authors: H-K. Kim, E-S. Lee, C. Lim, Y. Han, J. Kim, J-H. Cheun, H-B. Lee, H-G. Moon, W. Han
Journal: Annals of Oncology (2022)
TCT-304 Non-Invasive Assessment of Microvascular Dysfunction After Optimal Coronary Artery Stent Deployment; Insight From Acetyl Salicylic Elimination Trial (ASET) Japan
Authors: Shinichiro Masuda, Jinying Zhou, Shigetaka Kageyama, Kai Ninomiya, Nozomi Kotoku, Pruthvi Chenniganahosahalli Revaiah, Yoshinobu Onuma, Patrick Serruys
Journal: Journal of the American College of Cardiology (2022)
217O Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC)
Authors: N.T. Ueno, W. Jacot, T. Yamashita, J. Sohn, E. Tokunaga, A. Prat, J. Tsurutani, Y.H. Park, H.S. Rugo, B. Xu, F. Cardoso, Z. Mitri, R. Mahtani, K. Dunton, Y. Wang, D. Gambhire, F. Cottone, N. Harbeck, D.A. Cameron, S. Modi
Journal: Annals of Oncology (2022)
231P Safety of CDK4/6 inhibitors and concomitant radiation therapy in patients affected by metastatic breast cancer
Authors: L. Visani, C. Becherini, E. Scoccimarro, M. Valzano, C. Saieva, I. Ratosa, D. Ribnikar, M. Orazem, T. Marinko, I. Desideri, V. Scotti, A. Morandi, M. Lambertini, I. Meattini, L. Livi
Journal: Annals of Oncology (2022)
Developing new COVID-19 vaccine against the variants is urgently needed rather than boosters: A longitudinal cohort study
Authors: Qiu-Yan Xu, Xin-Qi Zheng, Zhi-Juan Jia, Meng-Juan Wu, Yan-Yun Liu, Li-Li Liu, Li-Rong Lin, Tian-Ci Yang
Journal: Journal of Infection (2022)
837P Real-world evidence of encorafenib (E) plus binimetinib (B) in unresectable advanced or metastatic BRAFV600-mut melanoma in Spain (GEM 2002 - BECARE)
Authors: A. Soria, P. Sánchez Mauriño, J.J. Serrano, S. Sequero, J. Fra Rodríguez, V. Amezcua, G. Benítez, E. Espinosa, C. Aguayo, R. García Galindo, R. Díaz-Beveridge, T. Puértolas, A. Cunquero-Tomás, R. López Castro, G. Crespo, P. López, L. Gutiérrez Sanz, B. Campos, L. García, P. Cerezuela-Fuentes
Journal: Annals of Oncology (2022)
69MO 5-Hydroxymethycytosine analysis reveals stable epigenetic changes in tumor tissue that enable cfDNA cancer predictions
Authors: F. Feng, Y. Ning, Y. Xue, V. Friedl, D. Hann, B. Gibb, A. Bergamaschi, G. Guler, K. Hazen, A. Scott, T. Phillips, E. McCarthy, C. Ellison, R. Malta, A. Nguyen, V. Lopez, R. Cavet, S. Chowdhury, W. Volkmuth, S. Levy
Journal: Annals of Oncology (2022)
76P Second interim analysis of INFINITY: A registry on decision making and clinical impact of biomarker-driven precision oncology in routine clinical practice
Authors: U.M. Martens, J. Schröder, L. Sellmann, M. Reiser, S. Frank-Gleich, T. Decker, A. Schneeweiss, M. Schuler, S. Grebhardt, S. Woerner, S. Zacharias, N.W. Marschner, B. Kasenda, C. Vannier
Journal: Annals of Oncology (2022)
713P Pembrolizumab (Pembro) vs placebo (Pbo) as second-line treatment for sorafenib-treated advanced hepatocellular carcinoma (aHCC): 4.5-year follow-up from KEYNOTE-240
Authors: J. Edeline, R.S. Finn, M. Bouattour, A-L. Cheng, S.L. Chan, T. Yau, M. Garrido, J. Knox, B. Daniele, V. Breder, H.Y. Lim, S. Ogasawara, A. Odeleye-Ajakaye, I. Martinez-Forero, A.B. Siegel, P. Merle
Journal: Annals of Oncology (2022)
TCT-606 Transcarotid vs Transaxillary Access for Transcatheter Aortic Valve Replacement With a Self-Expanding, Supra-Annular Valve
Authors: Keith Allen, Daniel Watson, Amit Vora, Paul Mahoney, Adnan Chhatriwalla, Jonathan Schwartz, Antoine Keller, Nishtha Sodhi, Ruth Eisenberg, Michael Caskey
Journal: Journal of the American College of Cardiology (2022)
717P Phase II study of transhepatic artery chemoembolization (TACE) combined with tislelizumab (TIS) and lenvatinib (LEN) in patients with unresectable hepatocellular carcinoma(uHCC)
Authors: X. Nong, J-L. Xie, Y-M. Zhang, J-C. Liang, Z-L. Pan, Z-M. Zhang
Journal: Annals of Oncology (2022)
97P Pan-cancer landscape of clonal tumor mutational burden (cTMB)
Authors: A.R. Parikh, K. Murugesan, J.F. Hopkins, Z. Arshad, D.X. Jin, S.J. Klempner, D.A. Fabrizio, G.M. Frampton, J. He, M. Montesion
Journal: Annals of Oncology (2022)
130P Autoantibodies as potential biomarkers of high grade immune-related adverse events (irAEs) in metastatic melanoma patients treated with check point inhibitors (ICIs)
Authors: A. Gandhi, J. Taylor, M. Morici, A. Reid, T. Meniawy, M.A. Khattak, M. Millward, E.S. Gray, P. Zaenker
Journal: Annals of Oncology (2022)
696P Geriatric nutritional risk index as a prognostic factor in elderly patients with locally advanced head and neck cancer receiving definitive chemoradiotherapy with cisplatin
Authors: Y. Fujiwara, Y. Sato, N. Fukuda, N. Hayashi, X. Wang, K. Nakano, A. Ohmoto, T. Urasaki, M. Ono, J. Tomomatsu, T. Toshiyasu, H. Mitani, S. Takahashi
Journal: Annals of Oncology (2022)
687P Differential expression of PDL-1 between primary and recurrent/metastatic head and neck squamous cell carcinoma: Analysis of concordance and factors impacting on variations
Authors: P. Bossi, D. Mattavelli, S. Battocchio, M. Martini, S. Calza, L. Lorini, D. Baldassarra, G. Zigliani, C. Piazza, P. Morbini
Journal: Annals of Oncology (2022)
757P USFDA authorized compassionate use of SNK01 (autologous non-genetically modified natural killer cells with enhanced cytotoxicity) and checkpoint inhibitors in advanced heavily pre-treated sarcoma: A promising regimen
Authors: V.S. Chua, S.P. Chawla, E. Gordon, T.T. Kim, B. Gibson, P. Chang, P.Y. Song
Journal: Annals of Oncology (2022)
806P Updated toxicity profile and relapse-free survival outcomes using an adapted pyrexia management algorithm in patients with resected stage III BRAF V600E/K-mutant melanoma treated with adjuvant dabrafenib plus trametinib in COMBI-APlus
Authors: M. Del Vecchio, V.G. Atkinson, B. Ryll, A.M. Menzies, F. Aubin, V. Chiarion Sileni, V. Ferraresi, T. Lesimple, G. Rinaldi, P. Saiag, C. Robert, C. Dutriaux, H.J. Gogas, L. Demidov, A. Gupta, H. Banerjee, S. Sudhir, F. Miranda, M.R. Lau, J.J. Grob
Journal: Annals of Oncology (2022)
113P Pembrolizumab in microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) advanced solid tumors: An update of the phase II KEYNOTE-158 trial
Authors: M. Maio, P.A. Ascierto, D. Motola Kuba, N. Penel, P.A. Cassier, G.M. Bariani, A. De Jesus-Acosta, T. Doi, F. Longo Muñoz, W.H. Miller, D-Y. Oh, M. Gottfried, L. Yao, F.J. Jin, A. Gozman, A. Marabelle
Journal: Annals of Oncology (2022)
724P Anti-PD-1 antibody SHR-1210 combined with apatinib as adjuvant treatment in patients with hepatocellular carcinoma at high risk of recurrence after radical resection: Preliminary results from a multicenter, randomized, controlled phase II trial
Authors: H. Zhao, S. Du, Z. Zhu, L. Jiang, X. Che, H. Qian, J. Song, D. Liu, Y. Zhang, P. Zhang, Y. Sun, W. Zhang, Y. Tang
Journal: Annals of Oncology (2022)
691P DNA-based peripheral blood epigenetic immuno-profiling of recurrent/metastatic (R/M) squamous cell carcinoma of head and neck (SCCHN) treated with anti-programmed death (PD)-1 therapy
Authors: K. Sehgal, Z. Zhang, K. Shirai, S. Donnelly, R. Butler, M.K. Lee, A. Molinaro, J.K. Wiencke, D.C. Koestler, L.A. Salas, B.C. Christensen, K.T. Kelsey, R. Haddad
Journal: Annals of Oncology (2022)
700P Prognostic miRNA signature score in patients with HNSCC
Authors: T. Siripoon, W. Worakitchanon, W. Panvongsa, L. Arsa, N. Trachu, A. Wongpan, N. Jinawath, A. Chairoungdua, N. Ngamphaiboon
Journal: Annals of Oncology (2022)
719P Tyrosine kinase inhibitors and/or immune checkpoint inhibitors is required for improving efficacy of transarterial chemoembolization for hepatocellular carcinoma: A large-scale multicenter real-world study of 582 patients
Authors: G. Yuan, R. Li, M. Zang, Q. Li, X. Hu, W. Fan, W. Huang, J. Ruan, H. Pang, J. Chen
Journal: Annals of Oncology (2022)
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and elaboration
Authors: Jan P. Vandenbroucke, Erik von Elm, Douglas G. Altman, Peter C. Gøtzsche, Cynthia D. Mulrow, Stuart J. Pocock, Charles Poole, James J. Schlesselman, Matthias Egger
Journal: International Journal of Surgery (2014)

Much medical research is observational. The reporting of observational studies is often of insufficient quality. Poor reporting hampers the assessment of the strengths and weaknesses of a study and the generalisability of its results. Taking into account empirical evidence and theoretical considerations, a group of methodologists, researchers, and editors developed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) recommendations to improve the quality of reporting of observational studies. The STROBE Statement consists of a checklist of 22 items, which relate to the title, abstract, introduction, methods, results and discussion sections of articles. Eighteen items are common to cohort studies, case–control studies and cross-sectional studies and four are specific to each of the three study designs. The STROBE Statement provides guidance to authors about how to improve the reporting of observational studies and facilitates critical appraisal and interpretation of studies by reviewers, journal editors and readers. This explanatory and elaboration document is intended to enhance the use, understanding, and dissemination of the STROBE Statement. The meaning and rationale for each checklist item are presented. For each item, one or several published examples and, where possible, references to relevant empirical studies and methodological literature are provided. Examples of useful flow diagrams are also included. The STROBE Statement, this document, and the associated Web site (http://www.strobe-statement.org/) should be helpful resources to improve reporting of observational research.
Epidermal Growth Factor Receptor Status in Operable Invasive Breast Cancer
Authors: Raj S. Rampaul, Sarah E. Pinder, Pete M. Wencyk, Rob I. Nicholson, Roger W. Blamey, John F. Robertson, Ian O. Ellis
Journal: Clinical Cancer Research (2004)

Epidermal Growth Factor Receptor (EGFR) expression has been studied extensively for its prognostic value, yet large overviews still indicate that it has no prognostic significance in contrast to data from individual studies (1). Several reasons account for this such as differences in sample size, study design and methodology, influence of adjuvant therapy, and short follow-up. To help address some of these issues, we examined a historical series of 254 cases of primary operable breast cancer in women receiving no adjuvant therapy where long-term follow-up (median, 180 months) was available. All cases were ages <70, well characterized with triple node sampling, and had been followed up annually. EGFR status was determined using routine immunohistochemistry (E30 antibody; Biogenix) and a semiquantitative scoring system: 0, 1, 2, 3 [2 and 3 were considered positive (cytoplasmic staining)]. Eighty-two (n = 82) tumors showed positive immunoreactivity (32%). Univariate analysis showed no significant difference between EGFR status and tumor size or type, but significant associations with lymph node stage (P = 0.05), estrogen receptor (P < 0.001) and histologic grade (P < 0.001) were seen. In multivariate analysis with stage, grade, EGFR, and estrogen receptor included, only stage and grade were independently significant for disease-free survival. For overall survival, the prognostic effect of grade and stage persisted and only in lymph node positive disease was EGFR independently significant (P = 0.008) for a survival advantage.We believe that there are important differences between studies that continue to plague the identification of patients who may benefit from EGFR testing. Tsutui et al. (2) recently reported on the EGFR status of 1029 patients, stating that EGFR had independent significance; however, this dataset included the confounding influence of adjuvant therapy, with short follow-up and grade was not assessed.Ferrero et al. (3) examined a similar size set (n = 780) and found EGFR to have no prognostic significance. We found EGFR to be significant only in lymph node-positive disease and when compared with traditional histopathological prognostic factors such as grade, size, and lymph node stage, the β coefficient was small (0.2), indicating that the pure prognostic impact of EGFR status is insignificant in routine practice compared to histological factors.
Characterization of γ-Aminobutyric Acid Type A Receptor–Associated Protein, a Novel Tumor Suppressor, Showing Reduced Expression in Breast Cancer
Authors: Christiane Klebig, Susanne Seitz, Wolfgang Arnold, Nicole Deutschmann, Manuela Pacyna-Gengelbach, Siegfried Scherneck, Iver Petersen
Journal: Cancer Research (2005)

Abstract Frequent allelic loss of the chromosomal region 17p13 in breast cancer has suggested that more tumor suppressor genes, besides p53, are located in this region. By doing suppression subtractive hybridization to detect differentially expressed genes between the breast cancer cell line CAL51 and a nontumorigenic microcell hybrid CAL/17-1, we identified the gene for the γ-aminobutyric acid type A (GABAA) receptor associated protein (GABARAP), located on 17p13.1. GABARAP displayed high expression levels in the microcell hybrid CAL/17-1 but only weak expression in CAL51 and other breast cancer cell lines tested. Furthermore, we observed large vesicles in CAL/17-1 by immunofluorescence staining, whereas no signal could be detected in the tumor cell line. GABARAP mRNA expression and protein expression were significantly down-regulated in invasive ductal and invasive lobular carcinomas compared with normal breast tissue measured by semiquantitative reverse transcription–PCR and immunohistochemistry, respectively. We assessed that neither mutations in the coding region of the gene nor hypermethylation of CpG islands in the promoter region are responsible for loss of gene expression in CAL51; however, 5-aza-2′-deoxycytidine treatment was effective in gene up-regulation, suggesting a methylation-dependent upstream effect. Stable transfection of GABARAP into CAL51 resulted in an increase of gene expression and remarkably influenced the ability of colony formation in soft agar and the growth rate in vitro and, moreover, suppressed the tumorigenicity of the cells in nude mice. In summary, our data suggest that GABARAP acts via a vesicle transport mechanism as a tumor suppressor in breast cancer.
H2O2-activated in situ polymerization of aniline derivative in hydrogel for real-time monitoring and inhibition of wound bacterial infection
Authors: Aihui Wang, Guishi Fan, Hongli Qi, Hongyan Li, Congcong Pang, Zhongkai Zhu, Shichen Ji, Hong Liang, Bang-Ping Jiang, Xing-Can Shen
Journal: Biomaterials (2022)
The Statistical Trends of Protein Evolution: A Lesson from AlphaFold Database
Authors: Qian-Yuan Tang, Weitong Ren, Jun Wang, Kunihiko Kaneko
Journal: Molecular Biology and Evolution (2022)

The recent development of artificial intelligence provides us with new and powerful tools for studying the mysterious relationship between organism evolution and protein evolution. In this work, based on the AlphaFold Protein Structure Database (AlphaFold DB), we perform comparative analyses of the proteins of different organisms. The statistics of AlphaFold-predicted structures show that, for organisms with higher complexity, their constituent proteins will have larger radii of gyration, higher coil fractions, and slower vibrations, statistically. By conducting normal mode analysis and scaling analyses, we demonstrate that higher organismal complexity correlates with lower fractal dimensions in both the structure and dynamics of the constituent proteins, suggesting that higher functional specialization is associated with higher organismal complexity. We also uncover the topology and sequence bases of these correlations. As the organismal complexity increases, the residue contact networks of the constituent proteins will be more assortative, and these proteins will have a higher degree of hydrophilic-hydrophobic segregation in the sequences. Furthermore, by comparing the statistical structural proximity across the proteomes with the phylogenetic tree of homologous proteins, we show that, statistical structural proximity across the proteomes may indirectly reflect the phylogenetic proximity, indicating a statistical trend of protein evolution in parallel with organism evolution. This study provides new insights into how the diversity in the functionality of proteins increases and how the dimensionality of the manifold of protein dynamics reduces during evolution, contributing to the understanding of the origin and evolution of lives.
FDA Approval Summary: Mobocertinib for Metastatic Non–Small Cell Lung Cancer with <i>EGFR</i> Exon 20 Insertion Mutations
Authors: Elizabeth S. Duke, Liza Stapleford, Nicole Drezner, Anup K. Amatya, Pallavi S. Mishra-Kalyani, Yuan-Li Shen, Kimberly Maxfield, Jeanne Fourie Zirkelbach, Youwei Bi, Jiang Liu, Xinyuan Zhang, Hezhen Wang, Yuching Yang, Nan Zheng, Kelie Reece, Emily Wearne, Jacqueline J. Glen, Idara Ojofeitimi, Barbara Scepura, Abhilasha Nair, Rama Kamesh Bikkavilli, Soma Ghosh, Reena Philip, Richard Pazdur, Julia A. Beaver, Harpreet Singh, Martha Donoghue
Journal: Clinical Cancer Research (2022)

Abstract On September 15, 2021, the FDA granted accelerated approval to mobocertinib (Exkivity, Takeda Pharmaceuticals USA, Inc.) for the treatment of adult patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. The approval was based on data from Study AP32788–15–101 (NCT02716116), an international, non-randomized, multi-cohort clinical trial that included patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations. The overall response rate in 114 patients whose disease had progressed on or after platinum-based chemotherapy was 28% [95% confidence interval (CI), 20%–37%] with a median duration of response of 17.5 months (95% CI, 7.4–20.3). The most common adverse reactions (&amp;gt;20%) were diarrhea, rash, nausea, stomatitis, vomiting, decreased appetite, paronychia, fatigue, dry skin, and musculoskeletal pain. Product labeling includes a Boxed Warning for QTc prolongation and torsades de pointes. This is the first approval of an oral targeted therapy for patients with advanced EGFR exon 20 insertion mutation–positive NSCLC.
Error in Discussion
Journal: JAMA Network Open (2022)

Investigation titled "Incubation Period of COVID-19 Caused by Unique SARS-CoV-2Strains: A Systematic Review and Meta-analysis," 1 published August 22, 2022, there was an error in the language describing the mean incubation period of COVID-19 among infected children vs the general population, which should have been described as longer.This article has been corrected.
Lipopeptide liposomes-loaded hydrogel for multistage transdermal chemotherapy of melanoma
Authors: Yifei Ni, Wanzhu Zhao, Wenjing Cheng, Chengyu Deng, Zhuoyang Ying, Lei Li, Xulei Wang, Chunmeng Sun, Jiasheng Tu, Lei Jiang
Journal: Journal of Controlled Release (2022)
Moral disciplining: The cognitive and evolutionary foundations of puritanical morality
Authors: Léo Fitouchi, Jean-Baptiste André, Nicolas Baumard
Journal: Behavioral and Brain Sciences (2022)

Abstract Why do many societies moralize apparently harmless pleasures, such as lust, gluttony, alcohol, drugs, and even music and dance? Why do they erect temperance, asceticism, sobriety, modesty, and piety as cardinal moral virtues? According to existing theories, this puritanical morality cannot be reduced to concerns for harm and fairness: It must emerge from cognitive systems that did not evolve for cooperation (e.g., disgust-based “purity” concerns). Here, we argue that, despite appearances, puritanical morality is no exception to the cooperative function of moral cognition. It emerges in response to a key feature of cooperation, namely that cooperation is (ultimately) a long-term strategy, requiring (proximately) the self-control of appetites for immediate gratification. Puritanical moralizations condemn behaviors which, although inherently harmless, are perceived as indirectly facilitating uncooperative behaviors, by impairing the self-control required to refrain from cheating. Drinking, drugs, immodest clothing, and unruly music and dance are condemned as stimulating short-term impulses, thus facilitating uncooperative behaviors (e.g., violence, adultery, free-riding). Overindulgence in harmless bodily pleasures (e.g., masturbation, gluttony) is perceived as making people slave to their urges, thus altering abilities to resist future antisocial temptations. Daily self-discipline, ascetic temperance, and pious ritual observance are perceived as cultivating the self-control required to honor prosocial obligations. We review psychological, historical, and ethnographic evidence supporting this account. We use this theory to explain the fall of puritanism in western, educated, industrialized, rich, and democratic (WEIRD) societies, and discuss the cultural evolution of puritanical norms. Explaining puritanical norms does not require adding mechanisms unrelated to cooperation in our models of the moral mind.
Clinical Predictors of Recurrent Supraventricular Tachycardia in Infancy
Authors: Judson A. Moore, Sara B. Stephens, Naomi J. Kertesz, Danyelle L. Evans, Jeffrey J. Kim, Taylor S. Howard, Tam Dan Pham, Santiago O. Valdés, Caridad M. de la Uz, Tia T. Raymond, Shaine A. Morris, Christina Y. Miyake
Journal: Journal of the American College of Cardiology (2022)